Ly-GDI/RhoGDI2/ARHGDIB Antibody (E-3): sc-271042

Ly-GDI Antibody (E-3) is a mouse monoclonal IgG1 antibody that detects Ly-GDI in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Ly-GDI, also known as Rho GDIβ, plays a crucial role in regulating the activity of Rho family GTPases, which are essential for various cellular processes including cell migration, adhesion, and cytoskeletal dynamics. By binding to these GTPases, Ly-GDI prevents their activation, thereby maintaining cellular homeostasis and influencing signaling pathways that govern cell proliferation and differentiation. Ly-GDI′s function is highlighted by expression primarily in hematopoietic cells, particularly in B and T lymphocyte cell lines, where Ly-GDI modulates immune responses. Additionally, Ly-GDI interacts with several Ras-like GTP-binding proteins, including Rho A, Rho B, and Cdc42, highlighting Ly-GDI′s role as a key regulator in the intricate network of cell signaling. Anti-Ly-GDI antibody (E-3)′s ability to effectively detect Ly-GDI across multiple species makes this product an invaluable tool for researchers studying the dynamics of cell signaling and the underlying mechanisms of various diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Ly-GDI/RhoGDI2/ARHGDIB Antibody (E-3) References:

1. Differential expression and regulation of GTPases (RhoA and Rac2) and GDIs (LyGDI and RhoGDI) in neutrophils from patients with severe congenital neutropenia.  |  Kasper, B., et al. 2000. Blood. 95: 2947-53. PMID: 10779444
2. LyGDI functions in cancer metastasis by anchoring Rho proteins to the cell membrane.  |  Ota, T., et al. 2004. Mol Carcinog. 39: 206-20. PMID: 15057873
3. Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma.  |  Ma, L., et al. 2007. Br J Haematol. 139: 217-23. PMID: 17897297
4. CARD9 facilitates microbe-elicited production of reactive oxygen species by regulating the LyGDI-Rac1 complex.  |  Wu, W., et al. 2009. Nat Immunol. 10: 1208-14. PMID: 19767757
5. LyGDI is a promising biomarker for ovarian cancer.  |  Zhen, H., et al. 2010. Int J Gynecol Cancer. 20: 316-22. PMID: 20375790
6. LyGDI, a novel SHIP-interacting protein, is a negative regulator of FcγR-mediated phagocytosis.  |  Mehta, P., et al. 2011. PLoS One. 6: e21175. PMID: 21695085
7. Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway.  |  Duan, W., et al. 2013. J Radiat Res. 54: 611-9. PMID: 23349340
8. 2-O-Octadecylascorbic acid represses RhoGDIβ expression and ameliorates DNA damage-induced abnormal spindle orientations.  |  Doi, N., et al. 2021. J Cell Biochem. 122: 739-751. PMID: 33586155
9. Differential functions of RhoGDIβ in malignant transformation and progression of urothelial cell following N-butyl-N-(4-hydmoxybutyl) nitrosamine exposure.  |  Hua, X., et al. 2023. BMC Biol. 21: 181. PMID: 37635218
10. RhoGDIβ inhibition via miR-200c/AUF1/SOX2/miR-137 axis contributed to lncRNA MEG3 downregulation-mediated malignant transformation of human bronchial epithelial cells.  |  Yang, Y., et al. 2024. Mol Carcinog. 63: 977-990. PMID: 38376344

The preferred Ly-GDI/RhoGDI2/ARHGDIB antibody is Ly-GDI/RhoGDI2/ARHGDIB Antibody (G-12): sc-376473.